-transparent.png){kind=logo}
Lymphokine activated killer (LAK) cells administered in conjunction with recombinant interleukin-2 can mediate the regression of metastatic tumor in some patients with advanced cancer. In these trials LAK cells were activated in medium containing 2% human type A or AB serum. We have found three commercially available, serum-free culture media which allow development of in vitro LAK activity by human peripheral blood lymphocytes. They are AIMV (Gibco), MASF-3 (Whitaker-MA Bioproducts) and HB-104 (Dupont). If 2-mercaptoethanol was added to these culture media they were also capable of generating murine LAK cells which were effective in reducing pulmonary metastases in the murine MCA-106 model. Although LAK cells generated in these media have not been tested in humans yet, potentially they could provide a safe, unlimited and less expensive source of culture fluid for generating the large numbers of LAK cells needed for human clinical trials.
L M Muul, and
K Nason-Burchenal, and
C Hyatt, and
S Schwarz, and
D Slavin, and
E P Director, and
S A Rosenberg
May 1991,
Cytotechnology,
L M Muul, and
K Nason-Burchenal, and
C Hyatt, and
S Schwarz, and
D Slavin, and
E P Director, and
S A Rosenberg
February 1986,
Journal of immunological methods,
L M Muul, and
K Nason-Burchenal, and
C Hyatt, and
S Schwarz, and
D Slavin, and
E P Director, and
S A Rosenberg
September 1996,
Journal of immunological methods,
L M Muul, and
K Nason-Burchenal, and
C Hyatt, and
S Schwarz, and
D Slavin, and
E P Director, and
S A Rosenberg
May 1988,
Journal of immunological methods,
L M Muul, and
K Nason-Burchenal, and
C Hyatt, and
S Schwarz, and
D Slavin, and
E P Director, and
S A Rosenberg
February 1989,
Cellular immunology,
L M Muul, and
K Nason-Burchenal, and
C Hyatt, and
S Schwarz, and
D Slavin, and
E P Director, and
S A Rosenberg
September 1985,
Clinical immunology and immunopathology,
L M Muul, and
K Nason-Burchenal, and
C Hyatt, and
S Schwarz, and
D Slavin, and
E P Director, and
S A Rosenberg
February 1994,
Clinical nutrition (Edinburgh, Scotland),
L M Muul, and
K Nason-Burchenal, and
C Hyatt, and
S Schwarz, and
D Slavin, and
E P Director, and
S A Rosenberg
February 1989,
Cytotechnology,
L M Muul, and
K Nason-Burchenal, and
C Hyatt, and
S Schwarz, and
D Slavin, and
E P Director, and
S A Rosenberg
September 1990,
Immunology,
L M Muul, and
K Nason-Burchenal, and
C Hyatt, and
S Schwarz, and
D Slavin, and
E P Director, and
S A Rosenberg
October 1989,
Blut,
